Abstract 10P
Background
There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment. There remains uncertainty regarding prognosis and treatment effect in small, node negative breast cancer. We described overall prognosis of small (<1cm), node (-), HER2 (+) breast cancer after curative surgery, and effect of adjuvant treatment.
Methods
We identified patients who fulfilled inclusion criteria (curative surgery, <1cm, N0, and HER2(+) breast cancer) by medical chart review. We collected data of baseline characteristics, receptor status, surgical method, histologic type, histologic and nuclear grade, adjuvant treatment (chemotherapy, radiotherapy, endocrine therapy, and trastuzumab. We compared baseline characteristics between patients with or without adjuvant treatment (Chi-square), and the prognosis between them (Kaplan meier curve and log-rank test). SPSS version 18.0 was used for statistical analysis.
Results
A total of 429 patients (pT1a=205, pT1b=222) were identified. In patients with pT1a, only 1 patient experienced systemic recurrence and death. No difference was observed in DFS and OS between patients with adjuvant chemotherapy and/or adjuvant trastuzumab. In pT1b, HR(-) patients (N = 52), longer DFS was observed in patients who received adjuvant chemotherapy (p = 0.013). There was no difference in DFS according to trastuzumab treatment (p = 0.441). No difference was found according to adjuvant treatment in overall or HR(+) pT1b patients.
Conclusions
In conclusion, our result showed overall prognosis of small(<1cm), node (-), and HER2+ breast cancer and patients with pT1b and HR(-) patients can benefit from adjuvant chemotherapy. Subsequent study with large sample size is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract